To determine whether eIF4A suppression could enhance the effects of KRAS G12C inhibition, we evaluated the eIF4A inhibitor eFT226 and the KRAS G12C inhibitor MRTX849 in a panel of NSCLC cell lines harboring the KRAS G12C–mutant allele. This evidence concerns the gene EIF4A1 and non-small cell lung carcinoma.